Consultant-Needed-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Morgan Stanley

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 02, 2020

            Details:

            Evofem Biosciences has announced pricing of an underwritten public offering of 28.5 million shares of its common stock at a price of $3.50/share. The gross proceeds are expected to be approximately $100 million. Evofem is committed to develop innovation women's healthcare product.